Sophiris Bio is a clinical-stage biopharmaceutical company focused on the development of products for the treatment of urological diseases. The company’s main product candidate is PRX302, currently in phase 3 clinical trial for treatment for the symptoms of benign prostatic hyperplasia (BPH), and for the treatment of localized low to intermediate risk prostate cancer. Sophiris has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302. For more information, visit the company’s website at www.sophirisbio.com